Autologous T cell therapy against CD19: Preliminary Phase I/II data

Preliminary data from 6 patients with refractory aggressive B cell NHL in the Phase I portion of the open-label, U.S. Phase I/II ZUMA-1 trial showed that a single infusion of IV KTE-C19 led to dose-li...